stockrow
Friday 6 November 2026
Export KOD’s income statement to Excel — free account
Kodiak Sciences Inc.
- EPS
- −1.94%
- Free cash flow
- −33.9%
Quarter to June 2026, against a year earlier
98.85
7.83
+8.60%
Follow KOD
Alert me
Kodiak Sciences Inc. (KOD) Return on equity
Kodiak Sciences Inc.'s return on equity over the twelve months to 30 June 2026 was −368.4%, down 218.9 percentage points from fiscal 2025 (−149.5%). Over the past ten years it has ranged from −458.1% (fiscal 2018) to 50.9% (fiscal 2017); the current reading is higher than 20% of that period. That is below the Biotechnology industry median of −50.1% and below the Healthcare sector median of −26.3%.
Return on equity, annual
Embed this chart
Annual newest first
| Period | Return on equity | Change (points) |
|---|---|---|
| FY2025 | −149.5% | (64.79) |
| FY2024 | −84.7% | (10.48) |
| FY2023 | −74.2% | (13.50) |
| FY2022 | −60.7% | (25.68) |
| FY2021 | −35.0% | (12.97) |
| FY2020 | −22.1% | (0.15) |
| FY2019 | −21.9% | 436.14 |
| FY2018 | −458.1% | (508.94) |
| FY2017 | 50.9% | 19.75 |
| FY2016 | 31.1% | — |
Against its own ten years
Low −458.1%
High 50.9%
Ten-year median
−47.9%
Current reading's percentile
20
Return on equity against peers
| Company | Return on equity |
|---|---|
| PTCT PTC Therapeutics, Inc. compare | 61.1% |
| LGND Ligand Pharmaceuticals Incorporated compare | 5.38% |
| BLTE Belite Bio, Inc. Sponsored ADR compare | 0.00% |
| ORKA Oruka Therapeutics, Inc. compare | −18.3% |
| CGON CG Oncology, Inc. compare | −26.4% |
| IMVT Immunovant, Inc. compare | −80.1% |
| IONS Ionis Pharmaceuticals, Inc. compare | −105.5% |
| KOD Kodiak Sciences Inc. | −368.4% |
| MIRM Mirum Pharmaceuticals, Inc. compare | −760.0% |
| Biotechnology industry median | −50.1% |
| Healthcare sector median | −26.3% |
| Market median | 0.51% |
What Return on equity is
ROE shows how much profit a company earns for its shareholders on the equity they have in the business.
Annual: Net Income Allotted to Shareholders ÷ Average Common Equity; TTM: Net Income Allotted to Shareholders ÷ Average Common Equity (latest quarter)